Biosimilars Are Fastest Growing Segment Fueling The Growth Of The Global Anticoagulant Market

https://www.coherentmarketinsights.com/market-insight/anticoagulant-market-5486
Anticoagulant Market



The global Anticoagulant Market is estimated to be valued at US$ 36830.47 Mn in 2023 and is expected to exhibit a CAGR of 9.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Anticoagulants are commonly used to treat and prevent blood clots, deep vein thrombosis, pulmonary embolism, myocardial infarction and stroke. It works by interfering with the clotting ability of blood. Anticoagulants find application in various therapeutic areas such as thrombosis, cardiovascualr diseases, respiratory diseases and others.

Market key trends:

One of the key trends in the anticoagulant market is the emergence of biosimilars. Biosimilars are biological medicines that are similar to already approved biological medicines (reference biological medicines). Biosimilars offer good efficacy and is less expensive as compared to reference medicines. Growing regulatory approval of biosimilars for various anticoagulants drugs such as warfarin, enoxaparin etc. for treatment of thrombosis, pulmonary embolism and other indications is fueling the growth of the anticoagulant market. For instance, in 2021, USFDA approved biosimilar version of warfarin available under the brand name Pradaxa.

Segment Analysis

The global anticoagulant market is segmented into drug class, distribution channel, and geography. By drug class, the market is classified into novel oral anticoagulants (NOACs) and vitamin K antagonists (VKAs). The NOACs segment dominated the market in 2022, accounting for around 60% share. NOACs are preferred more compared to VKAs due to their benefits such as fewer drug and food interactions, fixed dosing, and less frequent coagulation monitoring. By distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies commanded the largest share in 2022 owing to high preference of patients to purchase anticoagulant drugs from hospitals.

Key Takeaways

The global Anticoagulant Market Share reached US$ 36,830.47 million in 2023 and is expected to grow at a CAGR of 9.4% during the forecast period. Increasing prevalence of cardiovascular diseases, rising geriatric population, and growing adoption of NOACs are fueling the market growth.

Regional analysis: North America dominates the global market, capturing around 35% share in 2023 owing to advanced healthcare infrastructure and rising cases of atrial fibrillation (AF). Asia Pacific is projected to witness the fastest growth during the forecast period on account of improving healthcare facilities, huge patient pool, and increasing awareness about anticoagulant drugs.

Key players: Key players operating in the anticoagulant market are Pfizer Inc., Sanofi SA, Aspen Holdings, Abbott Laboratories, Leo Pharma AS, Alexion Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Company, Daiichi Sankyo Company, and Boehringer Ingelheim Pharmaceuticals Inc., among others. Major players are focusing on new product development and launches to gain a competitive edge in the market.


Comments

Popular posts from this blog

Agricultural Micronutrients Market Growth Accelerated By Increasing Need For Improved Soil Fertility

Dairy Alternative Market Expected To Reach USD 26.01 Billion By 2023

Antimicrobial Additives Market Growth Accelerated By Rising Demand From End-Use Industries